The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

Nov. 18, 2012
Applicant:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Inventors:

David R. Wise, New York, NY (US);

Patrick S. Ward, Cambridge, MA (US);

Craig B. Thompson, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 31/522 (2006.01); A61K 35/19 (2015.01); C12Q 1/6881 (2018.01); G01N 33/53 (2006.01); A61K 33/00 (2006.01); A61K 35/18 (2015.01); C12Q 1/6883 (2018.01); G01N 30/72 (2006.01); H01J 49/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); A61K 31/522 (2013.01); A61K 33/00 (2013.01); A61K 35/18 (2013.01); A61K 35/19 (2013.01); C12Q 1/6881 (2013.01); C12Q 1/6883 (2013.01); G01N 30/7206 (2013.01); G01N 33/5308 (2013.01); H01J 49/0036 (2013.01); G01N 2800/7038 (2013.01);
Abstract

The present invention provides biomarkers for sensitive, specific, accurate and quantitative diagnosis and assessment of chronic hypoxia. In particular, the present invention provides 2-hydroxyglutarate as a biomarker that is differentially produced in chronic hypoxia. Furthermore, embodiments of the invention are able to differentiate between chronic and acute hypoxia. Assays for levels of 2-hydroxyglutarate may be used alone or in conjunction with additional biomarkers of hypoxia to increase the precision of analysis. In particular embodiments of the invention, the level of 2-hydroxyglutarate and at least one second biomarker may be assayed to generate a hypoxic profile that can be compared to a reference or control profile, thereby diagnosing a subject as normoxic, chronically hypoxic, or acutely hypoxic.


Find Patent Forward Citations

Loading…